Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.35 |
| ▸ | KDM6A | O15550 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907051 | 0.89 | ALDH1A1 (0.41) | KDM4ENPC1USP2ALDH1A1LMNA | |
| SCHEMBL2902713 | 0.87 | CYP3A4 (0.42) | ABCB1ABCG2GPR119CYP3A4CYP3A5 | |
| SCHEMBL2904791 | 0.87 | CYP3A4 (0.42) | ABCB1ABCG2GPR119CYP3A4CYP3A5 | |
| SCHEMBL2908989 | 0.87 | KMT2A (0.44) | ABCB1ABCG2GPR119CYP3A4CYP3A5 | |
| SCHEMBL2908049 | 0.85 | ALDH1A1 (0.46) | ABCB1ABCG2GPR119CYP3A4CYP3A5 | |
| SCHEMBL2909115 | 0.83 | PTK2 (0.36) | CYP3A4KDM4ENPC1USP2ALDH1A1 | |
| SCHEMBL2907701 | 0.81 | ALDH1A1 (0.40) | CYP3A4ADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL2901687 | 0.80 | TSHR (0.38) | CYP3A4KDM4ENPC1ALDH1A1GAA | |
| SCHEMBL2908342 | 0.80 | ITGB2 (0.38) | KDM4ENPC1USP2ALDH1A1GAA | |
| SCHEMBL2902229 | 0.76 | SMN1; SMN2 (0.47) | KDM4ENPC1USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | SCD5 3141/4885ABCB1 821/4885ABCG2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.